格列齐特治疗2型糖尿病的临床疗效观察

Clinical effects of gliclazide sustained-release tablets on type 2 diabetes mellitus

目的对格列齐特缓释片治疗初发2型糖尿病患者的临床疗效进行观察。方法将118例初发2型糖尿病患者随机分为三组，分别应用格列齐特缓释片、瑞格列奈（进口）、重组人胰岛素治疗12周，测定三组受试者治疗前后的糖化血红蛋白、空腹及餐后2h血糖，并观察低血糖事件，对测试结果进行比较。结果格列齐特缓释片治疗组空腹和餐后2h血糖水平与重组人胰岛素治疗组差异无统计学意义（P〉0．05）。格列齐特缓释片治疗组空腹血糖控制优于瑞格列奈（进口）治疗组（P〈0．01）。重组人胰岛素对空腹血糖的控制优于瑞格列奈（进口）组（P〈0．01），但两组间餐后血糖水平无明显差异。结论对空腹血糖、餐后2h血糖及糖化血红蛋白的控制，格列齐特缓释片、重组人胰岛素、瑞格列奈（进口）均有较好疗效。

Objective To investigate the clinical effects of gliclazide sustained-release tablet for recently diagnosed type 2 diabetes mellitus. Methods 118 subjects with recently diagnosed type 2 diabetes and normal figure were divided into three groups. The three group subjects used gliclazide sustained-release tablet, repaglinide（imported） ,novolin 30R for 12 weeks,respectively. For all pretherapy and post-treatment cases, blood glucose and glycosylated hemoglobin were tested before meal. After two hours of meal, blood glucose was tested again. Meanwhile, hypoglycaemia event was inspected. The test results were analyzed by ＂mean±standard deviation＂ method. Results There are no significant difference（ P 〉 0.05） in fasting blood sugar and postprandial blood sugar（2h） level between the group using gliclazide sustained-release tablet and the group using novolin 30R. The clinical effects of both gliclazide sustained-release tablet and novolin 30R to fasting blood sugar are all better than that of repaglinide（imported） （P 〈 0.01 ）. But there are no significant difference in postprandial blood sugar（2h） level between the group of using gliclazide sustained-release tablet and the following two group： repaglinide（imported） and novolin 30R. Conclusion The investigation results show that gliclazide sustained-release tablet is better than repaglinide（imported） in fasting blood sugar. But for the effects of postprandial blood sugar（2h）, there is no significant difference between gliclazide sustained-release tablet, repaglinide（imported） and novolin 30R.